Atlas Trials

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

Clinical trial NCT05485350 · UNKNOWN

Trial details

NCT number
NCT05485350
Sponsor
Peking University Third Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Non-Small Cell Lung Cancer
Start date
2022-09-12
Primary completion
2023-09-21
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.